CN100590125C - 作为a2b腺苷受体拮抗剂的黄嘌呤衍生物 - Google Patents

作为a2b腺苷受体拮抗剂的黄嘌呤衍生物 Download PDF

Info

Publication number
CN100590125C
CN100590125C CN03826411A CN03826411A CN100590125C CN 100590125 C CN100590125 C CN 100590125C CN 03826411 A CN03826411 A CN 03826411A CN 03826411 A CN03826411 A CN 03826411A CN 100590125 C CN100590125 C CN 100590125C
Authority
CN
China
Prior art keywords
diketone
group
compound
methyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN03826411A
Other languages
English (en)
Chinese (zh)
Other versions
CN1771250A (zh
Inventor
拉奥·卡拉
陶佩里
埃尔法蒂赫·埃尔扎因
维布哈夫·瓦尔凯赫特卡
李晓芬
普拉巴·易卜拉欣
文卡塔·帕勒
肖登明
杰夫·扎布沃茨基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of CN1771250A publication Critical patent/CN1771250A/zh
Application granted granted Critical
Publication of CN100590125C publication Critical patent/CN100590125C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN03826411A 2003-05-06 2003-05-06 作为a2b腺苷受体拮抗剂的黄嘌呤衍生物 Expired - Fee Related CN100590125C (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/014085 WO2004106337A1 (en) 2003-05-06 2003-05-06 Xanthine derivatives as a2b adenosine receptor antagonists

Publications (2)

Publication Number Publication Date
CN1771250A CN1771250A (zh) 2006-05-10
CN100590125C true CN100590125C (zh) 2010-02-17

Family

ID=33488737

Family Applications (1)

Application Number Title Priority Date Filing Date
CN03826411A Expired - Fee Related CN100590125C (zh) 2003-05-06 2003-05-06 作为a2b腺苷受体拮抗剂的黄嘌呤衍生物

Country Status (15)

Country Link
EP (1) EP1622908B1 (enExample)
JP (1) JP2006515316A (enExample)
CN (1) CN100590125C (enExample)
AT (1) ATE403656T1 (enExample)
AU (1) AU2003249604B2 (enExample)
CA (1) CA2524778C (enExample)
CY (1) CY1108457T1 (enExample)
DE (1) DE60322748D1 (enExample)
DK (1) DK1622908T3 (enExample)
ES (1) ES2311759T3 (enExample)
MX (1) MXPA05011860A (enExample)
NZ (1) NZ543416A (enExample)
PT (1) PT1622908E (enExample)
SI (1) SI1622908T1 (enExample)
WO (1) WO2004106337A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2415858C2 (ru) * 2005-06-16 2011-04-10 Си Ви Терапьютикс, Инк. Пролекарства антагонистов a2b рецептора аденозина
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
US20070208040A1 (en) * 2006-03-02 2007-09-06 Elfatih Elzein A2a adenosine receptor antagonists
WO2009088518A1 (en) * 2008-01-11 2009-07-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for the treatment of cancer
US8871751B2 (en) 2008-01-18 2014-10-28 The Board Of Trustees Of The University Of Illinois Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
BRPI0909157A2 (pt) * 2008-03-26 2015-11-24 Advinus Therapeutics Private Ltd compostos heterocíclicos como antagonistas de receptores de adenosina
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
US8859566B2 (en) 2009-03-13 2014-10-14 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
US8796290B2 (en) 2009-11-09 2014-08-05 Advinus Therapeutics Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
AU2011303420B2 (en) 2010-09-13 2014-03-20 Impetis Biosciences Ltd. Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications
EP2970303B3 (en) * 2013-03-15 2018-08-01 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof
ES2580702B1 (es) 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
EP3389664A4 (en) 2015-12-14 2020-01-08 Raze Therapeutics Inc. MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
US11045472B2 (en) * 2017-05-05 2021-06-29 Arcus Biosciences, Inc. Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
US20210040097A1 (en) * 2018-03-05 2021-02-11 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
CN113727999A (zh) 2019-01-11 2021-11-30 奥默罗斯公司 用于治疗癌症的方法和组合物
CN118459463B (zh) * 2024-07-10 2024-09-06 山东中医药大学附属医院 一种化合物及其制备方法和治疗2型糖尿病的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4878296A (en) * 1988-04-22 1989-11-07 The United States Of America As Represented By The Secretary Of The Navy Apparatus and method for locating the axis of symmetry (center of circular cross section) of three dimensional objects

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
WO1995011681A1 (en) * 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
ES2189079T3 (es) * 1998-04-24 2003-07-01 Leuven K U Res & Dev Efectos inmunosupresores de derivados de xantina 8-sustituidos.
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
KR100883292B1 (ko) * 2001-06-29 2009-02-11 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ２ｂ 아데노신 수용체 길항제로서의 퓨린 유도체
PT1444233E (pt) * 2001-11-09 2011-09-29 Gilead Palo Alto Inc Antagonistas de receptor de adenosina a2b
WO2003063800A2 (en) * 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4878296A (en) * 1988-04-22 1989-11-07 The United States Of America As Represented By The Secretary Of The Navy Apparatus and method for locating the axis of symmetry (center of circular cross section) of three dimensional objects

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
1,3-dialkylxanthine derivatives. jacobson k.drug development research,Vol.47 No.1. 1999 *

Also Published As

Publication number Publication date
NZ543416A (en) 2009-01-31
EP1622908A1 (en) 2006-02-08
HK1092137A1 (en) 2007-02-02
DE60322748D1 (de) 2008-09-18
AU2003249604B2 (en) 2011-06-30
MXPA05011860A (es) 2006-02-17
JP2006515316A (ja) 2006-05-25
PT1622908E (pt) 2008-11-14
EP1622908B1 (en) 2008-08-06
ATE403656T1 (de) 2008-08-15
AU2003249604A1 (en) 2005-01-21
SI1622908T1 (sl) 2008-12-31
CN1771250A (zh) 2006-05-10
DK1622908T3 (da) 2008-11-17
ES2311759T3 (es) 2009-02-16
CA2524778A1 (en) 2004-12-09
WO2004106337A1 (en) 2004-12-09
CA2524778C (en) 2013-01-29
CY1108457T1 (el) 2014-04-09

Similar Documents

Publication Publication Date Title
CN100590125C (zh) 作为a2b腺苷受体拮抗剂的黄嘌呤衍生物
EP1444233B1 (en) A2b adenosine receptor antagonists
US8324224B2 (en) A2B adenosine receptor antagonists
US6977300B2 (en) A2B adenosine receptor antagonists
AU2002359365A1 (en) A2B adenosine receptor antagonists
US20040176399A1 (en) A2B adenosine receptor antagonists
WO2005042534A2 (en) A2b adenosine receptor antagonists
US7304070B2 (en) A2B adenosine receptor antagonists
AU2011224104B2 (en) A2B adenosine receptor antagonists
HK1092137B (en) Xanthine derivatives as a2b adenosine receptor antagonists
HK1071127B (en) A2b adenosine receptor antagonists
NZ573577A (en) Xanthine derivatives as A2B adenosine receptor antagonists suitable for treating conditions such as asthma and diarrhoea

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: GILEAD PALO ALTO CO., LTD.

Free format text: FORMER NAME: CV PHARMACEUTICAL CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: American California

Patentee after: Cv Therapeutics Inc.

Address before: American California

Patentee before: CV Therapeutics Inc.

ASS Succession or assignment of patent right

Owner name: GILEAD SCIENCES, INC.

Free format text: FORMER OWNER: GILEAD PALO ALTO, INC.

Effective date: 20140529

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20140529

Address after: American California

Patentee after: Gilead Sciences Corporation

Address before: American California

Patentee before: Cv Therapeutics Inc.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100217

Termination date: 20200506

CF01 Termination of patent right due to non-payment of annual fee